Cost–effectiveness of obinutuzumab plus bendamustine in Chinese patients with relapse and refractory follicular lymphoma

Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review

(2022) Andrew Davies et al.   Future Oncology

Early progression in follicular lymphoma in the absence of histological transformation or high‐risk Follicular Lymphoma International Prognostic Index still has a favourable outcome

(2022) Ana Muntañola et al.   BRITISH JOURNAL OF HAEMATOLOGY

Results of R-ESHAP as salvage therapy in refractory/relapsed follicular lymphoma: a real-world experience on behalf of GELCAB group

(2020) A. Muntañola et al.   ANNALS OF HEMATOLOGY

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

(2019) Emmanuel Bachy et al.   JOURNAL OF CLINICAL ONCOLOGY

Sustained Overall Survival Benefit of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Final Results of the Gadolin Study

(2019) Laurie H Sehn et al.   BLOOD

Transformation of follicular lymphoma – Why does it happen and can it be prevented?

(2018) Brian K. Link   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway

(2018) Fredrik Salvesen Haukaas et al.   Applied Health Economics and Health Policy

A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study

(2015) Kimihiro Matsumoto et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance)

(2015) John P. Leonard et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab With or Without Bevacizumab for the Treatment of Patients With Relapsed Follicular Lymphoma

(2014) John D. Hainsworth et al.   Clinical Lymphoma Myeloma & Leukemia

Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial

(2012) Pier Zinzani et al.   Journal of Hematology & Oncology

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

(2011) W. Alduaij et al.   BLOOD

Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study

(2010) Marinus H.J. van Oers et al.   JOURNAL OF CLINICAL ONCOLOGY